November 2024

Week in Review: FDA approves ATTR-CM drug | Surgeons make history | Compensation trends | Honoring a pioneer cardiologist ()
FDA approves new PFA system | Watchman data highlight bleeding benefit | Boston Scientific makes a move ()
Progress for Abbott's balloon-expandable TAVR valve | Overcoming imaging challenges | Contrast injections & coronary injuries ()
Week in Review: Patient injuries lead to recall | SAVR bests TAVR | Key takeaways from AHA 2024 | FDA clears AI screening tool ()
Week in Review: Payment cuts & beyond | Isotope shortage may be over | TAVR valves after 5 years | Fraud lands doc in prison ()
Week in Review: Higher payments for CCTA | Lessons from EARLY TAVR | FDA approves another PFA system ()
October's Top Stories: FDA’s tirzepatide decision | Compensation rises | TAVR survival dips | Why are there so many recalls? ()
Week in Review: FDA approves all-in-one PFA system | TAVR for asymptomatic AS | Cardiologist gets life in prison ()